PARTNERSHIP OPPORTUNITIES
Despite the approval of KRAS G12C monotherapies, the momentum to develop first and best-in-class RAS-targeting therapies grows, drawing in new and distinguished biopharma. As they gear-up to defeat the holy grail in precision oncology, they need support in computational technologies, screening platforms, assay development, protein analysis, chemical biology solutions and pre-clinical and clinical services.
Owing to this, the 6th Annual RAS-Targeted Drug Development Summit served as a central hub to showcase your expertise and benchmark your brand as a key solutions provider, and thought-leader, through our bespoke commercial packages.
Benefit From Market Intelligence: Hear how and where biopharma are searching for services and solutions to facilitate their efforts to develop, validate and clinically progress novel small molecules, cell therapies and vaccines
Showcase Your World-Class Solutions: Differentiate your discovery, pre-clinical and clinical services from other solution providers to leverage your business from competitors
Generate Commercial Collaborations: Meet prospective clients during structured networking breaks, bespoke meetings and informal networking receptions
Who You Could Have Met:
If you offer relevant services and would like to leverage your company within the RAS-targeted space, contact us to discuss a bespoke commercial package to promote your company at next year’s 7th RAS-Targeted Drug Development Summit
For more information, email sponsor@hansonwade.com.
